Aspira Women's Health Inc.Find Ratings Reports
ASPIRA WOMENS HEALTH INC's gross profit margin for the second quarter of its fiscal year 2020 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. ASPIRA WOMENS HEALTH INC is extremely liquid. Currently, the Quick Ratio is 2.80 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 45.63% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY20||Q2 FY19|
|Net Sales ($mil)||0.75||1.14|
|Net Income ($mil)||-3.83||-4.31|
|Balance Sheet||Q2 FY20||Q2 FY19|
|Cash & Equiv. ($mil)||10.94||16.18|
|Total Assets ($mil)||13.09||18.15|
|Total Debt ($mil)||2.2||1.39|
|Profitability||Q2 FY20||Q2 FY19|
|Gross Profit Margin||28.28||28.46|
|Return on Assets||-112.62||-74.38|
|Return on Equity||-202.88||-101.01|
|Debt||Q2 FY20||Q2 FY19|
|Share Data||Q2 FY20||Q2 FY19|
|Shares outstanding (mil)||100.53||94.38|
|Div / share||0.0||0.0|
|Book value / share||0.07||0.14|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||697664.0||1108403.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 60.25 indicates a significant premium versus the S&P 500 average of 3.92 and a significant premium versus the subsector average of 8.94. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. Upon assessment of these and other key valuation criteria, ASPIRA WOMENS HEALTH INC seems to be trading at a premium to investment alternatives.
|AWH NM||Peers 68.28||AWH NM||Peers 41.71|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AWH's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AWH's P/CF is negative making the measure meaningless.
|AWH NM||Peers 58.16||AWH NA||Peers 3.74|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AWH 60.25||Peers 8.94||AWH 21.06||Peers 19.36|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AWH is trading at a significant premium to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AWH is expected to keep pace with its peers on the basis of earnings growth.
|AWH 95.90||Peers 9.26||AWH 25.21||Peers 16.46|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AWH is trading at a significant premium to its subsector.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
AWH has a sales growth rate that significantly exceeds its peers.